Andrew Seeber

Andrew Seeber is a Senior Director at Transition Bio, Inc. with experience in various roles at research institutions and companies such as Harvard University, University of Zurich, and Friedrich Miescher Institute for Biomedical Research. Their expertise lies in studying DNA structure and dynamics, developing new microscopy techniques, and working on CRISPR-Cas9 gene editing projects. Andrew holds a PhD in Genetics from the University of Basel and a BSc in Biomedical Science from the University of Galway.